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e thank Dr. Leone and colleagues for their interest in our
ecently published article (1) and for their comments regarding
trial amyloid deposition being a potential mechanism for atrial
emodeling and atrial fibrillation (AF). They cited 2 studies in
upport of this theory. The study by Röcken et al. (2) found that
0 of 245 patients (16.3%) who underwent cardiac surgery had
myloid in the right atrial appendages, and of this group of 40, 14
35%) had AF. The study by Dr. Leone and colleagues consisted
f 72 patients with AF undergoing valvular surgery; 33 (46%) had
vidence of atrial amyloid, whereas only 6 of 52 (12%) patients in
inus rhythm with heart failure (serving as control subjects) had
trial amyloid (3). Both of these cross-sectional studies suggested
link between atrial amyloid and AF.
In contrast, Steiner and Hajkova (4) autopsied 100 hearts and
xamined the relationship between amyloid deposition and AF.
heir study did not show a statistical difference in either preva-
ence or severity of atrial amyloid between patients who had AF
nd those who did not.
The data from all 3 series are interesting and valuable, but
imited by: 1) their cross-sectional nature and, therefore, difficulty
ith interpretation of cause and effect; 2) the relatively small study
opulations; and 3) the fact that isolated atrial amyloid is exceed-
ngly common in older people and nearly universal in advanced
ges (86% in ages 81 to 90 years) (5). The aggregate data could
either prove nor refute the theory of amyloid as an important
ubstrate for atrial remodeling and AF development.
Furthermore, it is peculiar to note that the prevalence of AF in
myloid patients has not yet been shown to be of an inordinately
igh magnitude. One would surmise that if atrial amyloid is a
otent AF substrate, patients with cardiac amyloid should have a
1ery high prevalence of AF, especially as they almost invariably
ave large atria, and many also have restrictive diastolic physiology.
arlier publications on cardiac amyloid patients have not provided
dequate data regarding AF prevalence, because they either were
ery small series (6–10) or did not specifically evaluate the
revalence of AF (11–14). Our group has begun to review our own
myloid series regarding the prevalence/incidence of AF, and the
ata will be reported in the near future.
Indeed, the clinical impact of isolated atrial amyloid is uncer-
ain. The relationship of atrial amyloid to age and its role in left
trial remodeling and AF remain intriguing and warrant further
nvestigations.
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